You are here: Industry Insights > Jazz Pharmaceuticals

News List

Jazz' small cell lung cancer therapy wins US green light pharmatimes
June 17, 2020
Jazz Pharmaceuticals and PharmaMar have announced US approval of Zepzelca (lurbinectedin) for the treatment of adults with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Jazz Pharmaceuticals Announces Acquisition of Cavion americanpharmaceuticalreview
August 14, 2019
Jazz Pharmaceuticals announced the acquisition of Cavion through a merger with a Jazz subsidiary. Under the terms of the agreement, the former Cavion shareholders receive an upfront payment of $52.5 million and have the potential to receive additional pay
Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma americanpharmaceuticalreview
July 11, 2019
Jazz Pharmaceuticals announced the company has signed a definitive agreement under which Jazz has acquired Redx Pharma's (Redx) pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors.
Jazz Pharmaceuticals buys oncology asset from Redx in $206m deal pharmaceutical-technology
July 11, 2019
Jazz Pharmaceuticals has agreed to acquire a pre-clinical pan-RAF inhibitor programme from Redx Pharma intended for the treatment of certain cancers.
Jazz targets docs, consumers with branded Sunosi campaigns fiercepharma
July 09, 2019
Jazz Pharmaceuticals started prepping the ground last year for its new sleep drug launch, and now it's official: The biopharma's Sunosi is rolling out this week with branded doctor advertising, a stepped-up sales force and digital direct-to-consumer pitch
Jazz Pharma gets U.S. FDA approval for a drug that improves wakefulness biospectrumasia
March 25, 2019
Sunosi is expected to be commercially available in the U.S. following the final scheduling decision……
Jazz Pharmaceuticals gains FDA approval of sleep disorder drug Sunosi firstwordpharma
March 21, 2019
Jazz Pharmaceuticals announced that the FDA approved Sunosi (solriamfetol) to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy……
Jazz Pharmaceuticals Announces Board of Directors Appointment americanpharmaceuticalreview
February 18, 2019
Jazz Pharmaceuticals announced Anne O'Riordan, Senior Managing Director, Life Sciences of Accenture, was appointed to its Board of Directors...
Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea drugs
December 24, 2018
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its new drug application (NDA) for .......
NICE recommends Jazz Pharmaceuticals’ Vyxeos to treat AML pharmaceutical-technology
November 12, 2018
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Jazz Pharmaceuticals’ Vyxeos formulation to treat adults with two types of secondary Acute Myeloid Leukaemia (AML).

Previous page 1 2 Next page